Thrombotic Thrombocytopenic Purpura Market

 Market Overview:

The thrombotic thrombocytopenic purpura market reached a value of USD 417.3 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 650.6 Million by ​2035​, exhibiting a growth rate (CAGR) of 4.12% during ​2025-2035​.

The thrombotic thrombocytopenic purpura market has been comprehensively analyzed in IMARC's new report titled "Thrombotic Thrombocytopenic Purpura Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Thrombotic thrombocytopenic purpura (TTP) is a condition in which platelet clumps accumulate in small blood vessels. There are two types of this disease: immune-mediated TTP (acquired) and congenital TTP (inherited). Major symptoms include a significant decrease in the number of blood platelets (thrombocytopenia), inappropriate destruction of red blood cells (hemolytic anemia), and abnormalities in the neurological system, heart, and other organs caused by small clots that form in the smallest arteries. Individuals suffering from TTP might experience bleeding into the skin or mucus membranes, confusion, fatigue, weakness, fever, headache, pale skin color or yellowish skin color, shortness of breath, fast heart rate (over 100 beats per minute), etc. A diagnosis of this illness is primarily made through a combination of detailed patient history, clinical assessment, and blood tests. The healthcare professional may also use scoring systems, such as the PLASMIC score and French score, to assess the likelihood of ADAMTS13 deficiency in patients. Furthermore, urinalysis and renal function tests are often performed to reveal abnormalities like proteinuria, hematuria, and elevated creatinine.

The escalating prevalence of the mutations in the ADAMTS13 gene, which provides instructions for making an enzyme that is involved in the normal process of blood clotting, is primarily driving the thrombotic thrombocytopenic purpura market. In addition to this, the inflating utilization of corticosteroids, such as prednisone or high-dose dexamethasone, to help reduce inflammation and suppress the immune system is also creating a positive outlook for the market. Moreover, the widespread adoption of plasma exchange therapy, since it involves removing and replacing a person's blood plasma to eliminate harmful substances and replace them with healthy plasma, is further bolstering the market growth. Apart from this, the emerging popularity of monoclonal antibodies, like rituximab, that target B-cells and decrease the production of anti-ADAMTS13 autoantibodies to potentially prevent relapses and improve outcomes is acting as another significant growth-inducing factor. Furthermore, the rising application of nanotherapeutics on account of their numerous advantages, including enhanced drug efficacy, controlled release of drugs, and targeted drug delivery, is expected to drive the thrombotic thrombocytopenic purpura market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the thrombotic thrombocytopenic purpura market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for thrombotic thrombocytopenic purpura and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the thrombotic thrombocytopenic purpura market in any manner.

Recent Developments:

• In August 2024, Takeda stated that the European Commission (EC) had authorized ADZYNMA (recombinant ADAMTS13) for the treatment of ADAMTS13 deficiency in children and adults with congenital thrombotic thrombocytopenic purpura (cTTP).
• In May 2023, Takeda announced that the U.S. FDA had accepted the company’s Biologics License Application (BLA) for TAK-755, an enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura.

Drugs:

Adzynma is a human recombinant "A disintegrin and metalloproteinase with thrombospondin motifs 13" ADAMTS13 (rADAMTS13) that is used as preventative or on-demand enzyme replacement therapy in adults and children with congenital thrombotic thrombocytopenic purpura (cTTP). Adzynma restores ADAMTS13 activity, reducing the formation of pathologic blood clots, improving platelet count, and preventing life-threatening thrombotic episodes. This therapy offers a targeted approach to managing cTTP by directly addressing the underlying enzyme deficiency.

Cablivi (Caplacizumab) is a von Willebrand factor (vWF)-directed antibody fragment that is used to treat acquired thrombotic thrombocytopenic purpura (aTTP). Caplacizumab works by targeting the A1 domain of the ultra-large vWF, which inhibits its interaction with the glycoprotein Ib-IX-V receptor in platelets. Caplacizumab binds to the vWF with an affinity of 8.5 nM, making it highly target specific. The blocking of the vWF hinders the interaction between the von Willebrand factor and platelets, hence preventing platelet aggregation.

TAK-755 is being tested in clinical trials for the treatment of cTTP. It is intended to replace a missing or defective ADAMTS13 enzyme, allowing it to effectively cleave vWF. By replacing the ADAMTS13 enzyme, TAK-755 restores the body's ability to properly regulate vWF levels. This avoids the production of ultra-large vWF multimers, which can cause irregular blood clotting and cTTP-specific symptoms such as low platelet counts (thrombocytopenia), hemolytic anemia, and neurological impairment.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the thrombotic thrombocytopenic purpura market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the thrombotic thrombocytopenic purpura market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current thrombotic thrombocytopenic purpura marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the thrombotic thrombocytopenic purpura market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the thrombotic thrombocytopenic purpura market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the thrombotic thrombocytopenic purpura market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of thrombotic thrombocytopenic purpura across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of thrombotic thrombocytopenic purpura by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of thrombotic thrombocytopenic purpura by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with thrombotic thrombocytopenic purpura across the seven major markets?
• What is the size of the thrombotic thrombocytopenic purpura patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend of thrombotic thrombocytopenic purpura?
• What will be the growth rate of patients across the seven major markets?

Thrombotic Thrombocytopenic Purpura: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for thrombotic thrombocytopenic purpura drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the thrombotic thrombocytopenic purpura market?
• What are the key regulatory events related to the thrombotic thrombocytopenic purpura market?
• What is the structure of clinical trial landscape by status related to the thrombotic thrombocytopenic purpura market?
• What is the structure of clinical trial landscape by phase related to the thrombotic thrombocytopenic purpura market?
• What is the structure of clinical trial landscape by route of administration related to the thrombotic thrombocytopenic purpura market?